ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.

Zhen Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.